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Design of a randomised, double-blind,
crossover, placebo-controlled trial of
effects of sildenafil on cerebrovascular
function in small vessel disease: Oxford
haemodynamic adaptation to reduce
pulsatility trial (OxHARP)
Alastair Webb1 , David Werring2, Jesse Dawson3 ,
Alex Rothman4, Amy Lawson1 and Karolina Wartolowska1
Abstract
Background: Cerebral small vessel disease (SVD) is associated with increased cerebrovascular pulsatility, endothelial
dysfunction, and impaired vascular reactivity. Vasodilating phosphodiesterase inhibitors may improve cardiovascular
pulsatility and reactivity, and potentially reduce progression of SVD.
Hypothesis: Sildenafil, a PDE5 inhibitor, will reduce cerebrovascular pulsatility and increase cerebrovascular reactivity
compared to placebo, and is non-inferior to cilostazol, a PDE3 inhibitor.
Methods: OxHARP is a randomised, double-blind, crossover trial of sildenafil 50mg thrice daily, cilostazol 100mg twice
daily and placebo in 75 patients with mild to moderate small vessel disease and a previous lacunar or cryptogenic stroke
or TIA. Participants undergo a physiological assessment at baseline and on each treatment, including transcranial
Doppler ultrasound (TCD, DWL DopplerBox) to assess cerebrovascular pulsatility and reactivity to 4–6% carbon
dioxide. In up to 60 patients, cerebrovascular pulsatility, perfusion and reactivity will also be assessed by MRI.
Outcome measures: The primary outcome is difference in middle cerebral artery pulsatility (Gosling’s Pulsatility
Index, PI) after 3weeks of sildenafil versus placebo. Secondary outcomes including non-inferiority of sildenafil vs
cilostazol in effects on PI, percentage increase in MCA blood flow velocity and BOLD-fMRI response during inhalation
of 4–6% carbon dioxide.
Discussion: Reduction in cerebral pulsatility and increased cerebrovascular reactivity during treatment with
sildenafil would indicate potential benefit to prevent progression of SVD, suggesting a need for trials with clinical
outcomes.
Trial Registration OxHARP is registered with ClinicalTrials.org, NCT03855332
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Introduction
Chronic injury to the small vessels of the brain (‘small
vessel disease’) is associated with acute lacunar stroke,1
progressive cognitive decline,2 late-onset refractory
depression,3 functional impairment in daily living4
and increased mortality.5 Despite accounting for
approximately 30% of strokes and 40% of dementia,6
the underlying mechanism of small vessel injury is
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unclear. White matter hyperintensities are highly prev-
alent in the population, affecting the majority of
patients over the age of 65.7 However, even patients
with advanced imaging changes can remain functional-
ly independent,7 indicating a pre-clinical stage where
intervention may prevent progression of SVD and
resulting morbidity. Development of treatments to pre-
vent progression of SVD, particularly in ‘at risk’
patients with non-embolic strokes, is vital to reduce
the resulting morbidity in the population.
Hypertension is the strongest modifiable risk factor
for small vessel disease, but there is only limited evi-
dence that reduction of blood pressure alone signifi-
cantly reduces progression of SVD.8 Pulsatility of
blood flow to the brain is associated with small vessel
disease,9 resulting from increased transmission of the
pulsatile aortic waveform to the brain through stiff
conduit vessels. Secondly, small vessel disease is asso-
ciated with endothelial dysfunction, demonstrated by
impaired cerebrovascular reactivity and breakdown of
the blood-brain barrier.10 This may be secondary to
hypertension or arterial pulsatility, but it may also
reflect a local primary endotheliopathy.
Aortic pulsatility, aortic stiffness and transmission
of the aortic waveform are increased by reflection of
the outgoing aortic pressure wave from the systemic
small vessels back towards the aorta, increasing aortic
pulsatility. The resulting enhanced pulsatility reaching
the low resistance small vessels in the brain may cause
increased shear stress during systole and potential
hypoperfusion of tissues during diastole.11 Increased
aortic pulsatility may be modifiable by vasodilating
medications that delay the site and severity of wave
reflection. Such medications may also act upon muscu-
lar conduit vessels (distal internal carotid or middle
cerebral arteries (MCA)) to increase elasticity, improve
dampening of the aortic waveform and reducing pulsa-
tility at distal vessels. Phosphodiesterase inhibitors
such as sildenafil (a PDE5 inhibitor) and cilostazol (a
PDE3 inhibitor) enhance the cGMP pathways down-
stream of nitric oxide-dependent endothelial signalling,
potentially reducing wave reflection and enhancing
cerebrovascular reactivity, but the effect of sildenafil
on the intracranial vessels and brain vasculature has
not been adequately assessed. Cilostazol has been
shown to reduce cerebral pulsatility and reduce the
risk of stroke,12 but its additional antiplatelet effects
complicate how it could be used in conjunction with
current antiplatelet strategies. We therefore aim to test
the effect of sildenafil on cerebral pulsatility assessed by
transcranial ultrasound (TCD) and reactivity com-




OxHARP is a double-blind, randomised, placebo-
controlled, crossover study with physiological endpoints.
Participants receive placebo, sildenafil and cilostazol for
three weeks each in random sequence, with a minimum
1week washout period between treatments, and with a
dose-titration step at 1week (see Figure 1). To maintain
blinding, all medications are overencapsulated, and
administered three times daily, with a placebo dose at
mid-day during cilostazol treatment. On the final day of
treatment, participants undergo a physiological assess-
ment to determine cerebral pulsatility and cerebrovascu-
lar reactivity, with further physiological tests to assess
potential mechanisms and correlated physiological
effects. A subset of up to 60 patients may undergo an
MRI scan whilst on sildenafil and placebo, with up to 30
imaged on all three treatments.
Trial status
The first patient was included on 11th July 2019, with
15 patients recruited by 31st January 2020, including 13
participants recruited to the MRI substudy, and full
recruitment initially expected by December 2022. Due
to COVID-19, the study was halted in March 2020,
with resumption of recruitment in September 2020,
with 27 patients recruited by December 2020. As a
result, full recruitment is now planned by December
2023, allowing for further disruption to recruitment.
Ethical and regulatory approval
OxHARP is sponsored by the University of Oxford,
approved by the UK Health Research Authority and
South Central – Oxford C Research Ethics Committee
(19/SC/0022), and is registered with ClinicalTrials.org
(NCT03855332).
Population
75 patients with a history of a stroke or probable TIA
more than 1month previously, of cryptogenic or lacu-
nar aetiology, mild to moderate SVD evident on brain
imaging within the past 6 years and adequate temporal
bone windows.
Patient identification and recruitment
Potential participants are approached by their clinical
teams during an acute inpatient stay, at a TIA clinic or
at a follow-up clinic at the core site (Oxford) or region-
al patient identification centres (High Wycombe,
Swindon, Reading), or may be approached directly fol-
lowing participation in other research studies or from
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approved registries of patients. At the first visit, partic-
ipants are reviewed face-to-face by a study physician,
eligibility confirmed and full informed consent
obtained.
Participant schedule
The study comprises 4 visits over a minimum of
11weeks, including a baseline/screening visit and 3
‘on-treatment’ visits, separated by a minimum of
1week washout and 3weeks of treatment (1week
half-dose, 2weeks full dose) with each investigational
agent in randomised order (Figure 1). At the screening
or baseline visit, participants give full informed con-
sent, a medical history and physical examination, cog-
nitive assessment (Montreal Cognitive Assessment,
Digit Symbol Test, Fluid Intelligence), blood tests,
ECG and the core physiological assessment. At each
subsequent visit, participants have a clinical
assessment, blood tests and take their final treatment
dose 30minutes prior to the core physiological assess-
ment. Patients participating in the MRI substudy
undergo an MRI scan following the core physiological
assessment. Participants take their blood pressure at
home (twice daily, morning and evening, three readings
each time) during the week preceding each follow-up
visit (see Table 1).
Randomisation
For eligible patients (see Table 2), sequential study IDs
are randomly allocated to six treatment schedules
(Figure 1), stratified by allocation to the MRI sub-
study, at the point of production of treatment packs
by Huddersfield Pharmacy Manufacturing Unit, and
dispensed by the OUH Clinical Trial Pharmacy.
Study personnel and participants remain blinded to
treatment.
Figure 1. Flowchart of each patient’s progress through the study.
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Intervention
25mg oral sildenafil is taken three times daily for one
week, increased to 50mg three times daily for a further
2weeks, if tolerated and limiting side-effects do not
occur at the higher dose. The principal comparator is
placebo, three times daily. The secondary comparator
is 50mg cilostazol twice daily for one week, titrated to
100mg for 2 further weeks, with a matched placebo at
midday.
Blinding
Participants, the study team and endpoint assessors are
blinded to treatment. All medications are overencapsu-
lated and dispensed in identical, scheduled treatment
packs. In patients imaged only on sildenafil and place-
bo, the study team is not blinded to the cilostazol arm,
but remains blinded for sildenafil and placebo treat-
ment periods, whilst participants will remain blinded
to all treatments. If needed, the chief investigator
(AW) will determine if there is clinical indication for
code-breaking. Increased erections in response to sil-
denafil may result in incomplete blinding in men,
which will be assessed by participant reporting of any
change in sexual behaviour or frequency of erections.
Physiological assessment
Clinical tests. At each visit, all patients undergo a clinical
assessment, examination and routine blood tests
including full blood count, urea and electrolytes, liver
function test and CRP, with BNP or NT-proBNP,
gamma-GT, lipid profile, and HbA1C at baseline
(Table 1). In women of child-bearing potential, a preg-
nancy test is performed at the first visit. If an ECG
within the previous year is not available, or the medical
history indicates that a cardiac event may have
occurred since the last ECG, this is performed prior
to randomisation. Participants take their last medica-
tion dose at the start of each visit, 45minutes prior to
primary outcome measurement.
Physiological assessment
Middle cerebral artery flow velocity is assessed with
DiaMon 2MHz probes (DWL), as the highest velocity
waveform closest to a 50mm depth, via the transtem-
poral window. The basilar artery is insonated via the
suboccipital window, at the maximum velocity identi-
fiable at the depth closest to 80mm. Gosling’s
Pulsatility Index is derived: (peak flow velocity –
trough flow velocity)/mean flow velocity. Where bone
windows are adequate, bilateral monitoring of the
















Vital signs X X X X
Physical exam X X X X
Cognitive assessment X
Pregnancy test (X) (X) (X) (X) (X)
Laboratory tests X X X X X
ECG X
Randomisation X
7 days home BP monitoring twice daily for 1week X X X X
Study drug dispensation X X X
mRS (disability) X
NIHSS (stroke severity) only for stroke patients X
Drug accountability X X X
Concomitant medication X X X X X
Adverse events (AE) X X X
Pulse wave velocity/pulse wave analysis X X X X
Transcranial (TCD) ultrasound scan X X X X
Beat-to-beat BP monitoring X X X X
Peripheral vascular reactivity X X X X
MRI assessment (up to 60 patients) X X X
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middle cerebral artery is established with 2 probes held
by a comfortable headset, acquired over 10minutes
with concurrent ECG, non-invasive blood pressure
monitoring (FMS, Finometer Midi) and end-tidal
carbon dioxide monitoring (etCO2, AD Instruments
Gas Analyser ML206), via an AD Instruments
Powerlab 8/35.9,13 Reactivity to CO2 is assessed by
30 seconds of hyperventilation, followed by 2-minute
alternating periods of inhalation of medical air and
then 4% and 6% CO2, delivered via a respiratory cir-
cuit with a well-sealed, non-invasive ventilation mask.
Additional explanatory physiological measures
include arterial stiffness by carotid-femoral pulse
wave velocity, aortic blood pressure (Sphygmocor,
At-Cor Medical, Sydney, Australia) and measures of
cerebral autoregulation derived from the 10minutes
of concurrent monitoring of blood pressure and cere-
bral blood flow velocity (autoregulation index,14 trans-
fer function analysis15) Peripheral vascular reactivity is
assessed by flow mediated slowing (Vicorder, Skidmore
Medical, UK), where pulse wave velocity between two
brachial sites is determined before and after 5minutes
of supra-systolic occlusion.16
MRI assessment
Up to 60 consenting participants will be scanned on a
3-Tesla Siemens Prisma scanner (Oxford Wellcome
Centre for Integrative Neuroimaging (WIN)) at the
end of their sildenafil or placebo visits. Participants
will lie supine with foam pads, blankets and earplugs
to ensure comfort. During sequences that do not
require participants attention, they will be able to
watch a film using prism glasses. The principal MRI
outcome will be change in BOLD-fMRI signal during
inhalation of 6% CO2 in medical air, for 2 � 2minutes
periods versus 2-minute periods of medical air (TR
800ms, TE 30ms, multi-band acceleration factor 6,
Table 2. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
�Willing and able to give informed consent
� Male or Female, aged 18 years or above.
� MCA flow recordable on at least one
side
� Non-disabling, ischaemic stroke or TIA,
� >1 month prior to randomisation,
� either cryptogenic or lacunar
aetiology, confirmed clinically or on
brain imaging
� White matter hyperintensities on MRI
consistent with cerebral small vessel
disease:
 Age <60:
 MRI – Fazekas score 1–3 (max
2 points in periventricular or deep
score)
 CT – Blennow score 1–3 (max 2
points in periventricular or deep
score)
 Age
 >60: MRI - Fazekas score 1–4 (max
2 points in periventricular or deep
score)
 CT – Blennow score 1–4 (max
2 points in periventricular or deep
score)
� Pregnant or breastfeeding women,
� Women of childbearing age not taking contraception.
� Other major neurological or psychiatric conditions interfering with the study
design (e.g. multiple sclerosis)
� Other causes of stroke such as
 >50% luminal stenosis (NASCET)
 Major-risk cardioembolic source of embolism
 other specific causes of stroke (e.g. arteritis, dissection)
� Large vessel occlusion on MRA or CTA
� Modified Rankin Score >3 (requires assistance to walk)
� Unable to swallow
� Renal impairment (eGFR <35ml/min)
� Significant biochemical abnormalities (sodium <130, Kþ <2.5 or >5.5, LFTs
>3 x upper limit of normal range)
� Life expectancy <2 years
� Contraindication to active agents:
 Concurrent use of alphablocker, nitrates, ketoconazole, erythromycin,
anticoagulants or> 1 antiplatelet.
 Heart failure (NYHA 2–4), severe aortic stenosis, unstable angina, myo-
cardial infarction within 6 months, uncontrolled arrhythmias, haemody-
namically significant aortic/mitral valve disease
 Previous priapism, anatomical deformation of the penis
 History of non-arteritic ischaemic optic neuropathy
 Bilateral renal artery stenosis, Sickle cell disease, myeloma, leukaemia
 Hypotension (BP <90/60) or uncontrolled hypertension (BP >180/110
despite treatment with 3 antihypertensives)
� Scheduled elective surgery or other procedures requiring general anaesthesia
during the study.
� Participants participating in another research study involving an investigational
product in the past 12 weeks.
� Predisposition to intracerebral haemorrhage (previous ICH, likely cerebral
amyloid angiopathy) or intraocular haemorrhage (uncontrolled diabetic ret-
inopathy or neovascularisation)
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flip angle 50 degrees, 66 slices, in-plane resolution
2.4x2.4mm, slice thickness 2.4mm).17 The secondary
MRI outcome is cerebral arterial pulsatility during
high-frequency, multi-band BOLD-FMRI (TR
400ms, TE 22ms, multi-band acceleration factor 6,
flip angle 90, 30 slices, in-plane resolution
2.9x2.9mm, slice thickness 3mm).18,19
Participants undergo perfusion imaging at each visit
by pseudo-continuous Arterial Spin Labelling (pcASL)
sequence (TR 5100ms, TE 14ms, flip angle 90 degrees,
bolus duration 1800ms, post-labelling delay times:
300ms, 600ms, 900ms, 1200ms, 1500ms, 1800ms,
2100ms, 24 slices, slice in-plane resolution
3.4x3.4mm, slice thickness 4.5mm). Participants also
undergo structural imaging, split across the two visits:
T1-weighted scan for registration and volumetric
assessment (MPRAGE sequence; TR 2500ms, TE
4.37, voxel dimensions 1mm isometric; analysis by
FSL VBM); a T2-weighted-Fluid-Attenuated
Inversion Recovery scan for assessment of volume of
white matter hyperintensities (FLAIR: TR 5000ms, TE
397ms, voxel dimensions 1x1x1.1mm; analysis by
BIANCA)20; susceptibility weighted imaging (SWI:
TR 27ms, TE1 9.42ms, TE2 19.7ms, in-plane resolu-
tion 0.8x0.8mm, and slice thickness 3mm) to quantify
microhaemorrhages; and diffusion tensor imaging
(DTI; TR 3600ms, TE 92ms, 2x2x2mm voxel) scan,
to assess white matter microstructural integrity.
During pulsatility imaging, participants undergo
monitoring of pulse oximetry, respiratory bellows,
end-tidal CO2 via nasal cannulae (AD Instruments
Gas Analyser ML206) and continuous non-invasive
blood pressure by bilateral brachial cuffs.18 During
CO2-reactivity imaging, gas is delivered by a respirato-
ry circuit with sealed, non-invasive ventilation mask
and with end-tidal CO2 via a CO2 sampling line.21
Each MRI session lasts approximately 50minutes.
BOLD and ASL will be pre-processed prior to sta-
tistical analysis with motion correction (MCFLIRT),
B0 unwarping (BBR) and removal of extra-cerebral
tissue. Data will undergo spatial and temporal smooth-
ing, where appropriate. Perfusion on ASL will be quan-
tified by Bayesian Inference for Arterial Spin Labelling
(BASIL).
Statistical analysis plan
Primary outcome. The primary outcome is difference in
Gosling’s Pulsatility Index on sildenafil versus placebo
by paired T-test, on the side with a better-quality
recording as defined by a blinded assessor.
Secondary outcome. Non-inferiority of effects of silden-
afil versus cilastazol will be determined from the upper
limit of the 95% confidence interval, compared to a
0.08 unit change in MCA-PI.
Differences in reactivity to CO2 (percentage change
in mean flow velocity per percentage change in etCO2)
and MCA-PI on each treatment (sildenafil, cilostazol,
placebo) will be compared by mixed-effect general
linear models. Reactivity to CO2 on MRI will be deter-
mined individually by general linear models on a voxel-
wise basis (FEAT, FSL) for change in BOLD signal per
change in end-tidal CO2, stratified by tissue-type, and
compared between drug states in a general linear model
adjusting for within subject comparisons (FSL
FLAME), to test for an interaction between drug allo-
cation and CO2 response.
Exploratory outcomes. Effects of treatment on physiolog-
ical indices will be determined to assess mechanisms of
effects on pulsatility and reactivity by mixed-effect,
linear models across treatment phases for within-
subject comparisons, adjusted for repeated measures.
Physiological indices include home systolic and diastol-
ic blood pressure; carotid femoral pulse wave velocity;
aortic systolic blood pressure and pulse pressure; beat-
to-beat systolic and diastolic blood pressure variability
(coefficient of variation: standard deviation/mean);
peripheral flow mediated slowing16; measures of resting
state cerebral autoregulation in both time domain (Mx,
Dx, Sx) and frequency domains (transfer function anal-
ysis15) Interactions with concurrent treatment with vas-
odilating antihypertensives (ie amlodipine) will be
assessed.
Higher level MRI analyses will be performed by gen-
eral linear models, modelling mean effect for each
treatment, differential effect associated with period,
and differential effects associated with subject mean.
An F-test across the two main treatment periods will
estimate whether there is any treatment effect and an F-
test between the treatment period contrasts will esti-
mate whether there is an order effect across subjects.
Individuals who withdraw from sildenafil or placebo
treatment phases will be excluded from the primary
analysis, although participants with adverse events
who can not complete three weeks of treatment may
be included if a physiological assessment can be per-
formed after a minimum of 7 days of medication,
including three doses within the last 24 hours.
Participants without cilostazol exposure will be includ-
ed in analyses directly comparing sildenafil and place-
bo, but not analyses comparing all the stages of
treatment.
Sample size calculations
At a power level of 0.9, with a 2-sided significance of
5%, a clinically relevant 0.12 unit change in pulsatility
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index (equivalent to a �20% difference in risk of recur-
rent stroke), and conservatively allowing for a standard
deviation of differences in PI between repeated meas-
ures of 0.2, gives an estimated minimum sample size of
32 patients (paired t-test). Allowing for a 15% drop-
out rate, 38 patients would be required. A sample size
of 66 achieves 90% power to detect the non-inferiority
of sildenafil compared with cilostazol using a non-
inferiority margin of 0.08 (and mean of paired
differences 0) at a¼ 0.025 (for a 95% CI) with a
within-subject variance of 0.02. This equates to 75
patients in total with a 12% drop out rate.
A two-sided 5% significance level will be used for all
hypothesis tests.
Trial and data management
A Data and Safety Monitoring Board will review safety
and recruitment. Annual reviews will begin 12months
after initiation or the first visit of the first patient
(whichever is sooner), or at the request of the sponsor
or CI. If a decision to terminate the study is contemplat-
ed, this will be discussed with the CI and the sponsor
prior to a final decision being made. An independent
study monitor will review the study on an annual basis.
The advisory futility threshold is set at a projected
recruitment of <35 patients in 2 years (allowing for
unavoidable delays due to the COVID-19 pandemic).
Given the limited study size, no threshold is defined for
efficacy for study cessation. Any statistically significant
excess of SAEs in the treatment arm, or occurrence of
unexpected treatment-related SAEs of sufficient sever-
ity (in the view of the DSMB or sponsor), may also
result in early cessation of the study. If after 12months
the recruitment falls below the rate expected to com-
plete the study in 3 years, the secondary comparison
with cilostazol may be removed, and the overall study
size reduced to 50 participants. Any data collected to
that date will be retained and analysed according to the
original study plan.
Discussion and conclusions
This is the first study to directly compare the effects of
phosphodiesterase inhibitors on cerebral pulsatility and
reactivity in patients with cerebrovascular events and
small vessel disease. Both pulsatility and reactivity are
associated with cerebral small vessel disease in cohort
studies, with plausible biological mechanisms for a
causative effect. Previous trials have demonstrated
both a clinical benefit of phosphodiesterase
inhibition-dependent vasodilating medications on
stroke risk (CSPS,12 ESPS222) and cerebral small
vessel disease, with parallel effects on cerebral pulsatil-
ity (ECLIPSE23) and reactivity (LACI 121) If there is a
significant physiological effect of sildenafil (or cilosta-
zol) on these indices, this would support assessing the
effect of these medications in longer-term clinical stud-
ies to determine their efficacy in prevention of progres-
sion of cerebral small vessel disease, chronic cognitive
impairment, functional decline and recurrent stroke.
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